A. Disease Background
1) Brooks P. The burden of musculoskeletal disease – a global perspective. Clin Rheumatol. 2006; 25:778-781.
2) Longo, Fauci, Kasper, Hauser, Jameson, Loscanzo, editors. Harrison’s Principles of Internal Medicine, 18th Edition. New York: McGraw Hill Medical, 2012 pp.2828-2836.
3) Sarzi-Putini P, et al. Osteoarthritis: An overview of the disease and it treatment strategies. Semin Arthritis Rheum. 2005; 35:1-10
4) Chen FH, Tuan RS Mesenchymal stem cells in arthritic disease. Arthritis Res and Ther. 2008; 10:223-236
5) Carstairs A, Genever P. stem cell treatment for musculoskeletal disease. Current Opinion in Pharmacology. 2014, 16: 1-6
6) Lacitignola L, et.al. Cell therapy for tendonitis, experimental and clinical report. Vet Res Commun. 2008; Sup: 32 suppl 1: S 33-8.
7) Renzi S, et al. Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligament and tendons: a clinical report. Res Vet Sci. 2013 Aug 95(1):272-7.
8) Centeno CJ, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal cells. Pain Physician 2008: 11(3):343-353.
9) Emadedin M, et al. Intra-articular injection of autologous mesenchymal cells in six patients with knee osteoarthritis. Anthroscopy 2013: 29(4): 748-55.
10) Koh YG, et al. Mesenchymal stem cell injections improve symptoms of knee osteoarthriti. Arch Iraanian Med. 2012:15(7):422-428.
11) J o CH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof of concept clinical trial. Stem Cells 2013: DOI: 10.1002/stem.1634.
E. Platelet Rich Plasma
1) Bielecki TM, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances. J Bone Joint Surg BR. 2007-89-B: 417-20.
2) Chen L, et al. Antibacterial eǺect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro. J Diabetes Res 2013:doi. org/10.1155/2013/269527
3) Burnouf et al. Antimicrobial activity of platelet (PTLpoor Transfusion. 2013; 531(1):138-46 PLT lysate biomaterials against wound bacteria. Transfusion, 2013; 53(1) 138-46.
4) Yang Y. et al Antibacterial effect of autologous platelet-rich gel derived from health volunteers in vitro. Zhonggus Xiu Fu Chong Jian Waike Za Zhi. 2010;24(5):571-6.
F. Diagnostic Assessment
1) McConnells, et al. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); a review of its utility and measurement properties. Arthritis Rheum 2001; 45(5):453-461.
2) Raman J. Macdermid JC, Western Ontario Rotator Cu Index. Journal of Physiotherapy. 2012:58:102.
3) Meenan RF, German PM Mason JH. Measuring Health status in arthritis: the Arthritis Impact Measurement Scale. Arthritis Rheumatism 1980:23:146-52.
4) Ren XS, Kazis L. Meenan RF. Short-form Arthritis Impact Measurement Scale 2: tests of reliability and validity among patients with osteoarthritis. Arthritis care Res. 1999; 12(3): 163-71.
Disclaimer: Clinical studies have shown marked improvement in patients treated. All patients are enrolled in investigative research board clinical studies with specific protocols. This procedure is not FDA approved. Insurance companies do not pay for this procedure.
FDA Disclosure: Healthy Aging Medical Centers and its affiliate treatment centers are not offering stem cell therapy as a cure for any condition, disease, or injury. No statements or implied treatments in this brochure have been evaluated or approved by the FDA. This brochure contains no medical advice. All statements and opinions provided by this brochure are provided for educational and informational purposes only and we do not diagnose or treat via this brochure or via telephone. Healthy Aging Medical Centers and its affiliate treatment centers are offering patient funded research to provide individual patients with Stromal Vascular Fraction that contains their own autologous stem cells and growth factors and the treatment centers provide surgical procedures only and are not involved in the use or manufacture of any investigational drugs. Healthy Aging Medical Centers network does not claim that any applications, or potential applications, using autologous stem cells are approved by the FDA, or are even effective. We do not claim that these treatments work for any listed nor unlisted condition, intended or implied. It’s important for potential patients to do their own research based on the options that we present so that one can make an informed decision. Any decision to participate in our patient funded experimental protocols is completely voluntary.
ATTENTION: If you have ANY concern with stromal vascular fraction, any of our products, methods, website, brochure or technique and think we may be violating any U.S. law, please contact us so that we can investigate the matter or concern immediately.